share_log

EF Hutton Assumes Pasithea Therapeutics at Buy, Announces Price Target of $2

EF Hutton Assumes Pasithea Therapeutics at Buy, Announces Price Target of $2

EF Hutton 假設 Pasithea Therapeutics 處於買入狀態,宣佈目標股價爲2美元
Benzinga ·  2023/06/01 04:49

EF Hutton analyst Elemer Piros assumes Pasithea Therapeutics (NASDAQ:KTTA) with a Buy rating and announces Price Target of $2.

EF Hutton分析師埃勒默·皮羅斯假設Pasithea Therapeutics(納斯達克股票代碼:KTTA)的評級爲買入,並宣佈目標股價爲2美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論